Published in J Inorg Biochem on October 14, 2009
Metal-Arene Complexes with Indolo[3,2-c]-quinolines: Effects of Ruthenium vs Osmium and Modifications of the Lactam Unit on Intermolecular Interactions, Anticancer Activity, Cell Cycle, and Cellular Accumulation. Organometallics (2013) 0.86
Ruthenium polypyridyl complex inhibits growth and metastasis of breast cancer cells by suppressing FAK signaling with enhancement of TRAIL-induced apoptosis. Sci Rep (2015) 0.84
Design, synthesis and characterisation of new chimeric ruthenium(II)-gold(I) complexes as improved cytotoxic agents. Dalton Trans (2015) 0.82
In vitro and in vivo evaluation of water-soluble iminophosphorane ruthenium(II) compounds. A potential chemotherapeutic agent for triple negative breast cancer. J Med Chem (2014) 0.82
Anticancer activity of structurally related ruthenium(II) cyclopentadienyl complexes. J Biol Inorg Chem (2014) 0.80
Synthesis and anticancer activity of carbosilane metallodendrimers based on arene ruthenium(ii) complexes. Dalton Trans (2016) 0.78
Hydrogen bonding and anticancer properties of water-soluble chiral p-cymene Ru(II) compounds with amino-oxime ligands. Eur J Inorg Chem (2015) 0.77
Mir-375 enhances ruthenium-derived compound Rawq01 induced cell death in human ovarian cancer. Int J Clin Exp Pathol (2013) 0.76
Antimetastatic activity of novel ruthenium (III) pyridine complexes. Cancer Med (2016) 0.76
Os2 -Os4 Switch Controls DNA Knotting and Anticancer Activity. Angew Chem Int Ed Engl (2016) 0.75
Inhibition of cancer cell growth by ruthenium complexes. J Transl Med (2016) 0.75
Chlorambucil conjugates of dinuclear p-cymene ruthenium trithiolato complexes: synthesis, characterization and cytotoxicity study in vitro and in vivo. J Biol Inorg Chem (2016) 0.75
Cadmium-Resistant Pseudomonas putida Synthesizes Novel Cadmium Proteins. Science (1984) 2.07
Targeting ion channels in cancer: a novel frontier in antineoplastic therapy. Curr Med Chem (2009) 1.70
Inhibition of cancer cell growth by ruthenium(II) arene complexes. J Med Chem (2001) 1.61
Cardiopulmonary resuscitation in elderly patients hospitalized in the 1990s: a favorable outcome. J Am Geriatr Soc (1994) 1.55
Non-transferrin-bound iron in plasma or serum from patients with idiopathic hemochromatosis. Characterization by high performance liquid chromatography and nuclear magnetic resonance spectroscopy. J Biol Chem (1989) 1.54
In vitro and in vivo activity and cross resistance profiles of novel ruthenium (II) organometallic arene complexes in human ovarian cancer. Br J Cancer (2002) 1.45
Cisplatin binding sites on human albumin. J Biol Chem (1998) 1.45
Uraemia: is urea more important than we think? Lancet (1991) 1.42
Approaching tumour therapy beyond platinum drugs: status of the art and perspectives of ruthenium drug candidates. J Inorg Biochem (2011) 1.29
Use of high-resolution proton nuclear magnetic resonance spectroscopy for rapid multi-component analysis of urine. Clin Chem (1984) 1.26
Nuclear magnetic resonance studies of blood plasma and urine from subjects with chronic renal failure: identification of trimethylamine-N-oxide. Biochim Biophys Acta (1991) 1.24
Assignment of resonances for 'acute-phase' glycoproteins in high resolution proton NMR spectra of human blood plasma. FEBS Lett (1987) 1.24
Screening of lung cancer with low dose spiral CT: results of a three year pilot study and design of the randomised controlled trial ''Italung-CT''. Radiol Med (2005) 1.20
High resolution 1H n.m.r. studies of vertebrate blood and plasma. Biochem J (1983) 1.18
Proton-nuclear-magnetic-resonance studies of serum, plasma and urine from fasting normal and diabetic subjects. Biochem J (1984) 1.17
Regional cerebral blood flow in juvenile systemic lupus erythematosus: a prospective SPECT study. Single photon emission computed tomography. J Rheumatol (1998) 1.16
Role of television in childhood obesity prevention. Int J Obes Relat Metab Disord (2004) 1.13
113Cd NMR studies of reconstituted seven-cadmium metallothionein: evidence for structural flexibility. Biochemistry (1985) 1.13
Transferrin as a metal ion mediator. Chem Rev (1999) 1.11
In vitro cell cycle arrest, in vivo action on solid metastasizing tumors, and host toxicity of the antimetastatic drug NAMI-A and cisplatin. J Pharmacol Exp Ther (1999) 1.04
Inflammatory cells in experimental intervertebral disc injury. Spine (Phila Pa 1976) (1997) 1.04
Blood concentration and toxicity of the antimetastasis agent NAMI-A following repeated intravenous treatment in mice. Pharmacol Toxicol (2000) 1.02
A metallothionein containing a zinc finger within a four-metal cluster protects a bacterium from zinc toxicity. Proc Natl Acad Sci U S A (2001) 1.02
Multi-metal binding site of serum albumin. J Inorg Biochem (1998) 1.01
Proton NMR spectra of urine as indicators of renal damage. Mercury-induced nephrotoxicity in rats. Mol Pharmacol (1985) 1.00
Monitoring metabolic disease by proton NMR of urine. Lancet (1984) 1.00
Use of cylindrical titanium mesh and locking plates in anterior cervical fusion. Technical note. J Neurosurg (2001) 1.00
Ti(IV) uptake and release by human serum transferrin and recognition of Ti(IV)-transferrin by cancer cells: understanding the mechanism of action of the anticancer drug titanocene dichloride. Biochemistry (2000) 0.99
Ruthenium complexes can target determinants of tumour malignancy. Dalton Trans (2007) 0.99
Cytotoxicity and antitumor activity of some tetrahedral bis(diphosphino)gold(I) chelates. J Med Chem (1990) 0.99
Pertussis toxin export genes are regulated by the ptx promoter and may be required for efficient translation of ptx mRNA in Bordetella pertussis. Infect Immun (1995) 0.98
Interlobe communication in 13C-methionine-labeled human transferrin. Biochemistry (1996) 0.98
1H,13C-NMR and X-ray absorption studies of copper(I) glutathione complexes. Eur J Biochem (1996) 0.97
Interactions of bismuth complexes with metallothionein(II). J Biol Chem (1999) 0.97
1H NMR studies of human blood plasma. Assignment of resonances for lipoproteins. FEBS Lett (1987) 0.95
Multimodal rehabilitation for faecal incontinence: experience of an Italian centre devoted to faecal disorder rehabilitation. Tech Coloproctol (2003) 0.95
In vivo antitumor activity and in vitro cytotoxic properties of bis[1,2-bis(diphenylphosphino)ethane]gold(I) chloride. Cancer Res (1986) 0.95
1H NMR structure of an antifungal gamma-thionin protein SIalpha1: similarity to scorpion toxins. Proteins (1998) 0.93
Antimicrobial and anticancer activity of tetrahedral, chelated, diphosphine silver(I) complexes: comparison with copper and gold. J Inorg Biochem (1988) 0.93
Pharmacological Effects of the Ruthenium Complex NAMI-A Given Orally to CBA Mice With MCa Mammary Carcinoma. Met Based Drugs (2001) 0.93
Inhibition of endothelial cell functions and of angiogenesis by the metastasis inhibitor NAMI-A. Br J Cancer (2002) 0.91
Gamma-glutamyl transferase in the cell wall participates in extracellular glutathione salvage from the root apoplast. New Phytol (2009) 0.91
1H NMR of albumin in human blood plasma: drug binding and redox reactions at Cys34. FEBS Lett (1995) 0.91
Magnetic resonance imaging of renal osteodystrophy in children. Pediatr Radiol (1997) 0.90
The comparative evaluation of the physical and chemical properties of gold compounds. J Rheumatol Suppl (1982) 0.90
Molecular structures of porphyrin complexes in solution. An 1H nuclear magnetic resonance spectroscopic investigation of the interaction between 2,4,7-trinitrofluorenone and nickel(II) and cobalt(II) mesoporphyrin IX dimethyl esters. J Am Chem Soc (1973) 0.90
Effect of aging and diet on proton NMR spectra of rat urine. Magn Reson Med (1991) 0.89
Inhibition of B16 melanoma metastases with the ruthenium complex imidazolium trans-imidazoledimethylsulfoxide-tetrachlororuthenate and down-regulation of tumor cell invasion. J Pharmacol Exp Ther (2005) 0.89
Effects of some ruthenium chelates on MCa mammary carcinoma and on TLX5 lymphoma in mice. Anticancer Res (1993) 0.88
Biological role of adduct formation of the ruthenium(III) complex NAMI-A with serum albumin and serum transferrin. Invest New Drugs (2003) 0.88
Design, synthesis and structure of a zinc finger with an artificial beta-turn. J Mol Biol (1998) 0.88
Lack of In vitro cytotoxicity, associated to increased G(2)-M cell fraction and inhibition of matrigel invasion, may predict In vivo-selective antimetastasis activity of ruthenium complexes. J Pharmacol Exp Ther (2000) 0.88
T cell cross-reactivity to heavy metals: identical cryptic peptides may be presented from protein exposed to different metals. Eur J Immunol (1998) 0.88
Antineoplastic activity and toxicity of an organometallic complex of ruthenium(II) in comparison with cis-PDD in mice bearing solid malignant neoplasms. Eur J Cancer Clin Oncol (1984) 0.88
Antiangiogenic properties of selected ruthenium(III) complexes that are nitric oxide scavengers. Br J Cancer (2003) 0.87
NMR-invisible lactate in blood plasma. FEBS Lett (1988) 0.87
Effects of gold(I) antiarthritic drugs and related compounds on Pseudomonas putida. J Inorg Biochem (1992) 0.87
Rationalization of the strength of metal binding to human serum transferrin. Eur J Biochem (1996) 0.87
Investigation of the role of Bax, p21/Waf1 and p53 as determinants of cellular responses in HCT116 colorectal cancer cells exposed to the novel cytotoxic ruthenium(II) organometallic agent, RM175. Cancer Chemother Pharmacol (2005) 0.86
Inflammatory cells, motor weakness, and straight leg raising in transligamentous disc herniations. Spine (Phila Pa 1976) (2000) 0.85
Titanium(IV) targets phosphoesters on nucleotides: implications for the mechanism of action of the anticancer drug titanocene dichloride. J Biol Inorg Chem (2001) 0.85
Towards meeting the Paracelsus Challenge: The design, synthesis, and characterization of paracelsin-43, an alpha-helical protein with over 50% sequence identity to an all-beta protein. Proteins (1996) 0.85
NMR studies of body fluids. NMR Biomed (1989) 0.85
Quantitative high resolution 1H NMR urinalysis studies on the biochemical effects of cadmium in the rat. Mol Pharmacol (1989) 0.85
The effect of chloroplatinite on the 1H NMR spectrum of ribonuclease. Solvent accessibility of methionine residues. Biochim Biophys Acta (1974) 0.84
[Cicatricial stenosis of the small intestine of ischemic origin: 7 cases]. Ann Chir (1969) 0.84
Urinary excretion of acetaminophen and its metabolites as studied by proton NMR spectroscopy. Clin Chem (1984) 0.84
Cadmium-binding proteins in Pseudomonas putida: pseudothioneins. Environ Health Perspect (1986) 0.84
Sorbitol dehydrogenase is a zinc enzyme. EMBO J (1984) 0.84
Comparison of the prevalence of inflammatory cells in subtypes of disc herniations and associations with straight leg raising. Spine (Phila Pa 1976) (2001) 0.84
Orally administered microencapsulated lysozyme downregulates serum AGE and reduces the severity of early-stage diabetic nephropathy. Diabetes Metab (2008) 0.83
113Cd NMR studies on metal-thiolate cluster formation in rabbit Cd(II)-metallothionein: evidence for a pH dependence. Biochemistry (1988) 0.83
Oxalate- and Ga(3+)-induced structural changes in human serum transferrin and its recombinant N-lobe. 1H NMR detection of preferential C-lobe Ga3+ binding. Biochemistry (1993) 0.83
Microfluidic integration of photonic crystal fibers for online photochemical reaction analysis. Opt Lett (2012) 0.83
Comparison of the effects of intravenous alfentanil and esmolol on the cardiovascular response to double-lumen endobronchial intubation. Anaesthesia (2001) 0.82
Trp128Tyr mutation in the N-lobe of recombinant human serum transferrin: 1H- and 15N-NMR and metal binding studies. Protein Eng (1997) 0.82
NMR studies of a bacterial cell culture medium (LB broth): cyclic nucleotides in yeast extracts. FEMS Microbiol Lett (1990) 0.82
A new structural transition of serum albumin dependent on the state of Cys34. Detection by 1H-NMR spectroscopy. Eur J Biochem (1994) 0.82
Unexpectedly strong binding of a large metal ion (Bi3+) to human serum transferrin. J Biol Chem (1996) 0.82
Multiple solution conformations of the integrin-binding cyclic pentapeptide cyclo(-Ser-D-Leu-Asp-Val-Pro-). Analysis of the (phi, psi) space available to cyclic pentapeptides. Eur J Biochem (1996) 0.82
[1H,13C] NMR determination of the order of lobe loading of human transferrin with iron: comparison with other metal ions. FEBS Lett (1998) 0.81
Water-Soluble Ruthenium(III)-Dimethyl Sulfoxide Complexes: Chemical Behaviour and Pharmaceutical Properties. Met Based Drugs (1994) 0.81
Staging of breast cancer: what standards should be used in research and clinical practice? Ann Oncol (1998) 0.81
Reactions of gold(III) ions with ribonuclease A and methionine derivatives in aqueous solution. Biochim Biophys Acta (1977) 0.81
NMR studies of crab and plaice metallothioneins. Environ Health Perspect (1986) 0.81
Aldehydes from metal ion- and lipoxygenase-induced lipid peroxidation: detection by 1H-n.m.r. spectroscopy. Biochem J (1993) 0.81
Coordination of Zn2+ (and Cd2+) by prokaryotic metallothionein. Involvement of his-imidazole. J Biol Chem (1998) 0.81
88MHz 113Cd-n.m.r. studies of native rat liver metallothioneins. Biochem J (1983) 0.81
High resolution proton nuclear magnetic resonance studies of human cerebrospinal fluid. Clin Sci (Lond) (1987) 0.81
Anti-tumour activity in non-small cell lung cancer models and toxicity profiles for novel ruthenium(II) based organo-metallic compounds. Biochem Pharmacol (2005) 0.81
Evaluation of the cost of home care for terminally ill cancer patients. Support Care Cancer (1997) 0.80
HERG K+ channels and beta1 integrins interact through the assembly of a macromolecular complex. Ann N Y Acad Sci (2002) 0.80
[Results of surgical treatment and elements of prognosis in acute pancreatitis with necrosis. Apropos of a statiscal study of 121 cases]. Chirurgie (1974) 0.80
Inhibitory Effects of the Ruthenium Complex KP1019 in Models of Mammary Cancer Cell Migration and Invasion. Met Based Drugs (2009) 0.80
Two-dimensional proton nuclear magnetic resonance "maps" of acetaminophen metabolites in human urine. Clin Chem (1985) 0.80
Perforated gastric and duodenal ulcers treated by routine direct suture. Int Surg (1974) 0.80
Bathocuproine-assisted reduction of copper(II) by human albumin. J Biol Inorg Chem (2000) 0.80